Urbani Ginevra, Rondini Elena, Distrutti Eleonora, Marchianò Silvia, Biagioli Michele, Fiorucci Stefano
Dipartimento di Medicina e Chirurgia, Università degli Studi di Perugia, 06123 Perugia, Italy.
SC di Gastroenterologia ed Epatologia, Azienda Ospedaliera di Perugia, 06123 Perugia, Italy.
Cells. 2025 Apr 15;14(8):595. doi: 10.3390/cells14080595.
The current definition of a postbiotic is a "preparation of inanimate microorganisms and/or their components that confers a health benefit on the host". Postbiotics can be mainly classified as metabolites, derived from intestinal bacterial fermentation, or structural components, as intrinsic constituents of the microbial cell. Secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA) are bacterial metabolites generated by the enzymatic modifications of primary bile acids by microbial enzymes. Secondary bile acids function as receptor ligands modulating the activity of a family of bile-acid-regulated receptors (BARRs), including GPBAR1, Vitamin D (VDR) receptor and RORγT expressed by various cell types within the entire human body. Secondary bile acids integrate the definition of postbiotics, exerting potential beneficial effects on human health given their ability to regulate multiple biological processes such as glucose metabolism, energy expenditure and inflammation/immunity. Although there is evidence that bile acids might be harmful to the intestine, most of this evidence does not account for intestinal dysbiosis. This review examines this novel conceptual framework of secondary bile acids as postbiotics and how these mediators participate in maintaining host health.
后生元的当前定义是“一种对宿主具有健康益处的无生命微生物和/或其成分的制剂”。后生元主要可分为源自肠道细菌发酵的代谢产物,或作为微生物细胞固有成分的结构成分。次级胆汁酸脱氧胆酸(DCA)和石胆酸(LCA)是微生物酶对初级胆汁酸进行酶促修饰产生的细菌代谢产物。次级胆汁酸作为受体配体,调节包括GPBAR1、维生素D(VDR)受体和RORγT在内的一类胆汁酸调节受体(BARRs)的活性,这些受体由整个人体内的各种细胞类型表达。次级胆汁酸符合后生元的定义,鉴于其能够调节多种生物学过程,如葡萄糖代谢、能量消耗和炎症/免疫,对人类健康具有潜在的有益作用。尽管有证据表明胆汁酸可能对肠道有害,但这些证据大多未考虑肠道菌群失调的情况。本综述探讨了次级胆汁酸作为后生元这一新颖的概念框架,以及这些介质如何参与维持宿主健康。
Dig Dis Sci. 2021-3
Prog Lipid Res. 2024-7
Front Immunol. 2018-8-13
Biomed Pharmacother. 2024-12
Liver Res. 2025-1-28
Biochem Pharmacol. 2025-6
Cells. 2021-5-21
Ann Hepatol. 2017-11
Pharmaceuticals (Basel). 2025-5-21
Front Immunol. 2025-2-18
Nature. 2024-12-18
Biomed Pharmacother. 2024-12
J Agric Food Chem. 2025-1-15
Prog Lipid Res. 2024-7